Rose McNulty

New Jersey

Associate Editorial Director at MJH Life Sciences

Managing Editor at American Journal of Managed Care

✏️Muscle & Fitness, M&F Hers, Men's Fitness Instagram: @rose_mcnulty

Articles

Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS

2 days ago | ajmc.com | Rose McNulty

First-line luspatercept may offer significant advantages over erythropoiesis-stimulating agents (ESAs) for anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS), according to a real-world study presented at the 2025 American Society of Clinical Oncology annual meeting.1The study, which evaluated interim data from an ongoing retrospective review of medical records, supports earlier clinical trial findings of luspatercept’s efficacy.
CDC: Measles Vaccine Strongly Recommended for All International Travelers

4 days ago | patientcareonline.com | Rose McNulty

The CDC has updated its guidance on measles vaccination for international travelers, recommending that all travelers be fully vaccinated against measles regardless of their international destinations.1While the CDC recommends all US residents receive 2 doses of a measles-containing vaccine to protect against the highly contagious virus,2 the agency previously also stressed the vaccination’s importance for those traveling to countries with outbreaks.
FDA Launches Agency-Wide AI Tool to Aid in Scientific Review

4 days ago | ajmc.com | Rose McNulty

The FDA launched a generative artificial intelligence (AI) tool, dubbed Elsa, designed to help employees such as scientific reviewers and investigators work more efficiently, the agency announced in a press release on Monday. The tool, which was built within a high-security GovCloud environment, “modernizes agency functions and leverages AI capabilities to better serve the American people,” the release explained.
CDC Urges All International Travelers to Be Vaccinated Against Measles

4 days ago | ajmc.com | Rose McNulty

The CDC has updated its guidance on measles vaccination for international travelers, recommending that all travelers be fully vaccinated against measles regardless of their international destinations.1While the CDC recommends all US residents receive 2 doses of a measles-containing vaccine to protect against the highly contagious virus,2 the agency previously also stressed the vaccination’s importance for those traveling to countries with outbreaks.
Trastuzumab Deruxtecan Plus Pertuzumab Improves PFS vs Standard Care in HER2+ Breast Cancer

6 days ago | ajmc.com | Rose McNulty

Trastuzumab deruxtecan (Enhertu; AstraZeneca/Daiichi Sankyo) in combination with pertuzumab (Perjeta; Genentech) demonstrated significantly longer progression-free survival (PFS) compared with the current standard of care for patients with locally advanced or metastatic human epidermal growth factor receptor 2 (HER2)–positive breast cancer in the DESTINY-Breast09 trial (NCT04784715).1 The interim findings, which support the trastuzumab deruxtecan combination as a new standard of care, were...
Navigating Hope, Risk, and the Unknown in a Changing DMD Treatment Landscape

1 week ago | ajmc.com | Rose McNulty

As novel therapies, including gene therapy, emerge in the Duchenne muscular dystrophy (DMD) treatment space, patient and caregiver perspectives are of the utmost importance in treatment decision-making. Although such therapies have shown potential to slow disease progression, they also come with known and unknown risks.
Hurdles Remain Despite Progress in Gene Therapy for DMD

1 week ago | ajmc.com | Rose McNulty

Despite progress in research and clinical experience, challenges remain in optimizing the safety, efficacy, and long-term outcomes of adeno-associated virus (AAV) gene therapy for Duchenne muscular dystrophy (DMD), according to a review published in Molecular Therapy.1.DMD is a rare, inherited disorder that leads to progressive muscle weakness and premature death.
Genetic Testing for Hereditary Cancer Identifies Case of MDS

1 week ago | ajmc.com | Rose McNulty

Routine genetic testing for hereditary cancer risk led to an unexpected diagnosis of myelodysplastic syndrome (MDS) in a 68-year-old man with a history of multiple solid tumors, a case report published in npj Genomic Medicine described.1 The case highlights the importance of careful interpretation of test results and appropriate DNA sources in genetic testing. “To our knowledge, the diagnosis of MDS through hereditary cancer genetic testing has not been previously reported,” the authors wrote.
DMD Gene Therapy Shows Efficacy, Safety in Patients Treated at 2 Years Old

2 weeks ago | ajmc.com | Rose McNulty

Study participants with Duchenne muscular dystrophy (DMD) who were 2 years old at the time of treatment with delandistrogene moxeparvovec (Elevidys; Sarepta Therapeutics) showed promising biomarker results and no new safety signals, according to a press release from Sarepta.1 The new results come from Study 9001-103, also known as the ENDEAVOR trial (NCT04626674), a multicohort study evaluating dystrophin expression and safety after delandistrogene moxeparvovec treatment in patients with...
Lurbinectedin Plus Atezolizumab Maintenance Shows Improved Survival vs Atezolizumab in SCLC

2 weeks ago | ajmc.com | Rose McNulty

The phase 3 IMforte trial (NCT05091567) met its primary end points of improved independent review facility–assessed progression-free survival (IRF-PFS) and overall survival (OS) with lurbinectedin plus atezolizumab vs atezolizumab alone in patients with extensive-stage small cell lung cancer (ES-SCLC).1 Findings from the primary analysis of the open-label, randomized study will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held from May...